Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 679-514-8 | CAS number: 154279-60-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
NH-2 (trade name Clearlink 1000) caused vacuolative changes in various organs of rats at 10 mg/kg/day dose level in a 28-day repeated dose study by Keiji Shiraishi et al. (2002).
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Endpoint conclusion
- Dose descriptor:
- NOAEL
- 10 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
Additional information
Two studies have been conducted in order to evaluate repeated dose toxicity of Clearlink 1000. In the first study by Keiji Shiraishi et al. (2002) NH-2 (trade name Clearlink 1000) in olive oil was administered to male and female Crj:CD (SD) IGS rats by oral gavage with dose levels of 3, 10 and 30 mg/kg/day for 28-days.
No death occured during the study. No signs of test substance related toxicity were observed in autopsy or in urinanalysis. Body weight gain and food uptake were low in both sexes in the highest (30 mg/kg/day) dose level groups during the administration. Clinical signs (lowering of spontaneous motion, staining of nasal and peroral area, cyclopean eye and lacrimation in females, staining of lower abdomen and rough hair in males) were predominantly observed in the highest dose (30 mg/kg/day) group rats. Also increase in organ weights (relative weight of liver and kidneys, and absolute and relative weight of adrenals) were observed in the highest dose group (30 mg/kg/day) rats.Various hispopathological findings in several organs were reported, vacuolisation being the main effect.
Under the test conditions, the NOEL was indicated to be 3 mg/kg/day based on the presence of vacuolative changes in various organs of rats from the 10 mg/kg dose group. A review of the original study report was made at 2011 by George A. Parker. In the review summary report it is speculated that even the histopathological findings support the estimation of the NOEL, it should be noted that vacuolative changes of the type described in the report do not necessary indicate an adverse effect. Similar vacuolative changes have been observed in safety assessment studies of a number of marketed pharmaceutical products, and were determined to represent phospholipidosis. In addition, clinical pathology indications of hepatic injury were observed only in rats at the 30 mg/kg/day group. The absence of clinical pathology indications of hepatocellular injury in the 10 mg/kg/day group possibly indicates that the vacuolative changes were not adverse in that group. Based on this, the NOAEL is considered 10 mg/kg/day.
This study was selected as a key study since at the time of the submission of Clearlink 1000 dossier only draft report was available from the second study.
The study by F.M. van Ottedijk (2011) is combined 28-day repeated dose toxicity with the reproduction/developmental toxicity screening test. The data from this study will be included in the dossier once the final study report is available.
Repeated dose toxicity: via oral route - systemic effects (target organ) cardiovascular / hematological: lymph nodes; digestive: liver; respiratory: lung; urogenital: kidneys
Justification for classification or non-classification
Based on the study results of repeated exposure with rats (F.M. van Otterdijk et al., 2011) and according to Annex I of Regulation (EC) No 1272/2008 and Annex VI of Regulation 67/548/EEC no classification is required.
.Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.